At 4.7% CAGR, the Middle East & Africa Enteral Nutrition Market is Projected to be Worth US$ 569.24 Million by 2030, Says Business Market Insights
According to Business Market Insights research, the Middle East & Africa enteral nutrition market was valued at US$ 395.69 million in 2022 and is expected to reach US$ 569.24 million by 2030, registering a CAGR of 4.7% from 2022 to 2030. Rising cases of malnutrition and premature births and increasing prevalence of gastrointestinal diseases are among the critical factors attributed to the Middle East & Africa enteral nutrition market expansion.
Gastrointestinal diseases include Crohn's disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and certain cancer types. Patients with gastrointestinal diseases are at an elevated risk of nutritional deterioration as they are asked to fast before undergoing diagnostic tests. They may also face nutritional deterioration due to therapeutic dietary restriction and loss of appetite caused by anorexia or altered nutritional requirements, which can be a result of the disease itself. Thus, medical nutrition is recommended for these patients due to their inability to ingest food. Enteral routes are preferred to provide them with essential nutrients. Enteral feeding refers to the direct intake of food nutrients through the mouth or through a tube that passes the digestive tract (mouth to stomach/small intestine and then anus). This type of nutrition is preferred to provide treatment support for patients suffering from chronic ailments, such as neurological disorders, gastrointestinal diseases, and inherited metabolic diseases. Therefore, the surging prevalence of gastrointestinal diseases drives the growth of the enteral nutrition market.
On the contrary, complications associated with enteral feeding systems hampers the growth Middle East & Africa enteral nutrition market.
Based on product type, the Middle East & Africa enteral nutrition market is bifurcated into general and disease specific. The general segment held 57.3% share of the Middle East & Africa enteral nutrition market in 2022, amassing US$ 226.56 million. It is projected to garner US$ 323.96 million by 2030 to expand at 4.6% CAGR during 2022-2030.
In terms of application, the Middle East & Africa enteral nutrition market is segmented into gastrointestinal disorders, metabolic/inborn errors of metabolism, food allergy, renal disease, liver disease, oncology, neurology, and others. The gastrointestinal disorders segment held 30.3% share of the Middle East & Africa enteral nutrition market in 2022, amassing US$ 119.92 million. It is projected to garner US$ 171.34 million by 2030 to expand at 4.6% CAGR during 2022-2030.
Based on age group, the Middle East & Africa enteral nutrition market is bifurcated into adult and pediatric. The adult segment held 85.2% share of the Middle East & Africa enteral nutrition market in 2022, amassing US$ 337.17 million. It is projected to garner US$ 479.39 million by 2030 to expand at 4.5% CAGR during 2022-2030.
By distribution channel, the Middle East & Africa enteral nutrition market is segmented into hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held 58.1% share of Middle East & Africa enteral nutrition market in 2022, amassing US$ 230.02 million. It is projected to garner US$ 325.15 million by 2030 to expand at 4.4% CAGR during 2022-2030.
Based on country, the Middle East & Africa enteral nutrition market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia held 40.1% share of Middle East & Africa enteral nutrition market in 2022, amassing US$ 158.71 million. It is projected to garner US$ 224.92 million by 2030 to expand at 4.5% CAGR during 2022-2030.
Key players operating in the Middle East & Africa enteral nutrition market are Abbott Laboratories, Arla Foods amba, B Braun SE, Danone SA, Dr Schar AG, Fonterra Co-Operative Group Ltd, Fresenius SE & Co KGaA, Nestle SA, Perrigo Co Plc, Reckitt Benckiser Group Plc, and Royal FrieslandCampina NV, among others.
In Nov 2021, Fonterra and VitaKey Inc. announced a transformative dairy science collaboration to further unlock the benefits of Fonterra's probiotic strains. VitaKey specializes in precision delivery of nutrition - an emerging area of research that seeks to deliver the right nutrients, in the right amount, to the right part of the body at the right time.
In July 2023, Fonterra announced a new corporate ventures arm to incubate, scale and invest in ventures in the area of nutrition science.
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com
